Tags

Type your tag names separated by a space and hit enter

Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Expert Opin Investig Drugs. 2020 Oct; 29(10):1089-1098.EO

Abstract

INTRODUCTION

Atopic dermatitis (AD) is a chronic inflammatory skin disease mediated by multiple signals including janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. Current therapeutic armamentarium consists of a limited number of drugs which may result in the insufficient management of AD. Preclinical evidence regarding inhibition of JAK/STAT led to the development of a promising class of therapeutics, namely, JAK inhibitors. Baricitinib, a novel JAK1/JAK2 inhibitor is currently under investigation in AD clinical trials.

AREAS COVERED

This review offers an overview of Baricitinib and examines clinical efficacy and safety data in patients with moderate-to-severe AD.

EXPERT OPINION

Baricitinib showed promising preliminary data in terms of efficacy in phase II and III trials, with a very rapid onset of response and great improvements of itch and sleep disturbances. These aforementioned aspects combined with the advantage of an oral formulation have reduced drug production costs compared to biologic agents and could lead to consideration of baricitinib as a first line systemic treatment. Also, in some countries, it could be a therapeutic option in the case of contraindication or failure of conventional systemic drugs prior to biologic therapies. Data related to long-term safety and efficacy will be important to refine the place-in-therapy of this drug.

Authors+Show Affiliations

A. Gemelli IRCCS, UOC Di Dermatologia, Fondazione Policlinico Universitario , Rome, Italy. Dermatologia, Università Cattolica Del Sacro Cuore , Rome, Italy.A. Gemelli IRCCS, UOC Di Dermatologia, Fondazione Policlinico Universitario , Rome, Italy. Dermatologia, Università Cattolica Del Sacro Cuore , Rome, Italy.A. Gemelli IRCCS, UOC Di Dermatologia, Fondazione Policlinico Universitario , Rome, Italy. Dermatologia, Università Cattolica Del Sacro Cuore , Rome, Italy.A. Gemelli IRCCS, UOC Di Dermatologia, Fondazione Policlinico Universitario , Rome, Italy.A. Gemelli IRCCS, UOC Di Dermatologia, Fondazione Policlinico Universitario , Rome, Italy. Dermatologia, Università Cattolica Del Sacro Cuore , Rome, Italy.Dermatologia, Università Cattolica Del Sacro Cuore , Rome, Italy.A. Gemelli IRCCS, UOC Di Dermatologia, Fondazione Policlinico Universitario , Rome, Italy. Dermatologia, Università Cattolica Del Sacro Cuore , Rome, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32703039

Citation

Calabrese, Laura, et al. "Baricitinib: Therapeutic Potential for Moderate to Severe Atopic Dermatitis." Expert Opinion On Investigational Drugs, vol. 29, no. 10, 2020, pp. 1089-1098.
Calabrese L, Malvaso D, Chiricozzi A, et al. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis. Expert Opin Investig Drugs. 2020;29(10):1089-1098.
Calabrese, L., Malvaso, D., Chiricozzi, A., Tambone, S., D'Urso, D. F., Guerriero, C., & Peris, K. (2020). Baricitinib: therapeutic potential for moderate to severe atopic dermatitis. Expert Opinion On Investigational Drugs, 29(10), 1089-1098. https://doi.org/10.1080/13543784.2020.1800639
Calabrese L, et al. Baricitinib: Therapeutic Potential for Moderate to Severe Atopic Dermatitis. Expert Opin Investig Drugs. 2020;29(10):1089-1098. PubMed PMID: 32703039.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baricitinib: therapeutic potential for moderate to severe atopic dermatitis. AU - Calabrese,Laura, AU - Malvaso,Dalma, AU - Chiricozzi,Andrea, AU - Tambone,Sara, AU - D'Urso,Dario Francesco, AU - Guerriero,Cristina, AU - Peris,Ketty, Y1 - 2020/08/14/ PY - 2020/7/25/pubmed PY - 2021/3/4/medline PY - 2020/7/25/entrez KW - Atopic dermatitis KW - JAK KW - JAK inhibitors KW - baricitinib KW - small molecules SP - 1089 EP - 1098 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 29 IS - 10 N2 - INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin disease mediated by multiple signals including janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. Current therapeutic armamentarium consists of a limited number of drugs which may result in the insufficient management of AD. Preclinical evidence regarding inhibition of JAK/STAT led to the development of a promising class of therapeutics, namely, JAK inhibitors. Baricitinib, a novel JAK1/JAK2 inhibitor is currently under investigation in AD clinical trials. AREAS COVERED: This review offers an overview of Baricitinib and examines clinical efficacy and safety data in patients with moderate-to-severe AD. EXPERT OPINION: Baricitinib showed promising preliminary data in terms of efficacy in phase II and III trials, with a very rapid onset of response and great improvements of itch and sleep disturbances. These aforementioned aspects combined with the advantage of an oral formulation have reduced drug production costs compared to biologic agents and could lead to consideration of baricitinib as a first line systemic treatment. Also, in some countries, it could be a therapeutic option in the case of contraindication or failure of conventional systemic drugs prior to biologic therapies. Data related to long-term safety and efficacy will be important to refine the place-in-therapy of this drug. SN - 1744-7658 UR - https://www.unboundmedicine.com/medline/citation/32703039/Baricitinib:_therapeutic_potential_for_moderate_to_severe_atopic_dermatitis_ L2 - https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1800639 DB - PRIME DP - Unbound Medicine ER -